PA007513.m2a: In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Mouse IgG2a Kappa
The in vivo grade recombinant anti-mouse VEGF mouse IgG2a kappa monoclonal antibody was produced in mammalian cells.
Clone: B20-4.1.1.1.
Isotype: Mouse IgG2a Kappa.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: B20-4.1.1.1) specifically binds to mouse VEGF.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse VEGF protein.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Shipping: The in vivo grade recombinant anti-mouse VEGF antibodies (clone of B20-4.1.1.1) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody
Syd Labs provides the following anti-mouse VEGFA monoclonal antibodies:
In vivo grade recombinant anti-mouse VEGFA monoclonal antibodies (Clone B20-4.1.1.1))
In vivo grade recombinant anti-mouse VEGF-A monoclonal antibodies (Clone G6-31)
In vivo grade recombinant anti-mouse VEGF monoclonal antibodies (Clone G6-23)
Syd Labs provides the following anti-mouse PD-1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-1 / VEGF-A bispecific antibodies (Clone RMP1-14.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD1 / VEGFA bispecific antibodies (Clone 29F.1A12.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-23)
In vivo grade recombinant anti-mouse PD1 / VEGF bispecific antibodies (Clone 29F.1A12.1 / G6-23)
In vivo grade recombinant anti-mouse PD 1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-31)
In vivo grade recombinant anti-mouse PD-1 / VEGF A bispecific antibodies (Clone 29F.1A12.1 / G6-31)
Syd Labs provides the following anti-mouse PD-L1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-L1 / VEGF-A bispecific antibodies (Clone 10F.9G2.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-L1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-23)
In vivo grade recombinant anti-mouse PDL1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-31)
Syd Labs provides the following recombinant anti-mouse VEGF monoclonal antibodies for Flow Cytometry:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) for Flow Cytometry
Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Brolucizumab Biosimilar, research grade, VEGF-A Monoclonal Antibody
Faricimab Biosimilar, research grade, Human ANGPT2/VEGFA Monoclonal Antibody
References of anti-mouse VEGF antibody (Clone: B20-4.1.1.1):
A VEGFR2–MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice
Kuo, C. Y., et al. Mol Cancer Ther. 2024 Aug 2;23(8):1069-1082. doi: 10.1158/1535-7163.MCT-23-0564. PMID: 38791979
We examined the anti-VEGF-B-specific monoclonal antibody 2H10 in preclinical xenograft models of breast and colorectal cancer, in comparison with the anti-VEGF-A antibody bevacizumab. Cell surface expression of VEGFR-1 (orange) and VEGFR-2 (green) was explored in four cancer cell lines (DU4475, MDA-MB-231, COLO205, and HT29) by antibody staining and flow cytometry analysis. Non-specific staining was not observed with the IgG2a isotype control murine antibody. Here we investigated the VEGFR1 ligand VEGF-B, which we demonstrate to be expressed in tumor cells and in tumor stroma and vasculature across a range of tumor types. Complementary actions of dopamine D2 receptor agonist and anti-VEGF therapy on tumoral vessel normalization in a transgenic mouse model.
Tags: anti-mouse VEGF-B 2H10 antibody; anti-mouse VEGF-A (bevacizumab) antibody for cancer research
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Chen, C., et al. J Immunother Cancer. 2023 Apr;11(4):e006150. doi: 10.1136/jitc-2022-006150. PMID: 36990507
VEGF blockade using specific antibodies against VEGF or VEGFR2 increased HEVs in the TME and cytotoxic CD8(+) TILs, significantly improving the therapeutic efficacy of EAT strategies in preclinical models, supporting the clinical investigation of VEGF blockades to further enhance BsAb-based T cell immunotherapy. VEGF blockade enhances GD2-EAT infiltration into neuroblastoma and particularly, increased intratumoral CD8(+) T cells. BsAb-driven intratumoral T cell infiltration and in vivo antitumor response were evaluated using cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) carried out in BALB-Rag2 -/-IL-2R-γc-KO (BRG) mice. VEGF expression on human cancer cell lines was analyzed by flow cytometry, and VEGF levels in mouse serum were measured using VEGF Quantikine ELISA Kit.
Tags: anti-mouse VEGF (BVZ) antibody; anti-mouse VEGFR2 (DC101) antibody for cancer research
Anti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain
Jiang, X., et al. Clin Cancer Res. 2014 Aug 1;20(15):3887-3897. doi: 10.1158/1078-0432.CCR-13-1941. PMID: 25051973
VEGF inhibition by administration of B20-4.1.1, a monoclonal antibody that targets both human and murine VEGF, reduced radiation necrosis in a mouse model of intracranial glioblastoma. Mice were treated with either B20-4.1.1 (5 mg/kg, i.p., twice weekly) or IgG control starting one day before irradiation and continuing for 4 weeks. MRI was performed to assess the development of necrosis and edema in the brain post-irradiation. Tumor growth was significantly delayed in the B20-4.1.1-treated group compared to controls, as measured by bioluminescence imaging. Histological analysis confirmed reduced vascular permeability and necrosis in the brains of B20-4.1.1-treated mice.
Tags: anti-mouse VEGF B20-4.1.1 mAb in animal model; anti-mouse VEGF B20-4.1.1 in cancer research
A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models
Yu, L., et al. PLoS One. 2010 Feb 3;5(2):e9072. doi: 10.1371/journal.pone.0009072. PMID: 20140243
A humanized anti-VEGF rabbit monoclonal antibody (B20-4.1) was tested in NCI-H460 lung carcinoma and other human tumor xenograft models in nude mice to evaluate its anti-angiogenic and anti-tumor effects. Tumor growth inhibition was observed in a dose-dependent manner following twice-weekly intraperitoneal injections of B20-4.1 at 5 or 10 mg/kg. Microvessel density (MVD) was significantly reduced in tumors treated with B20-4.1, as assessed by anti-CD31 immunostaining. The antibody effectively neutralized both human and murine VEGF, ensuring complete blockade of VEGF signaling in the host-tumor microenvironment. In vivo efficacy was further confirmed by reduced tumor volume in treated mice compared to controls over a 3-week treatment period.
Tags: bioactivity of anti-mouse VEGF B20-4.1; anti-mouse VEGF B20-4.1 of low endotoxin
Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF
Liang, W. C., et al. J Biol Chem. 2006 Jan 13;281(2):951-961. doi: 10.1074/jbc.M508199200. PMID: 16357182
A cross-species VEGF-blocking antibody, B20-4.1.1, was developed to bind and block both human and murine VEGF with high affinity, and its effects were tested in A673, HM-7, and HPAC human tumor xenografts in nude mice. Complete inhibition of tumor growth was achieved in all tested xenograft models following twice-weekly administration of B20-4.1.1 at 5 mg/kg. The contribution of stromal-derived VEGF to tumor angiogenesis was quantified by comparing B20-4.1.1 with antibodies that selectively block human VEGF. Immunohistochemical analysis revealed a significant reduction in CD31-positive vessel density in B20-4.1.1-treated tumors. B20-4.1.1 treatment resulted in no detectable human or murine VEGF in the serum of treated mice, as measured by ELISA.
Tags: anti-mouse VEGF (B20-4.1.1) monoclonal antibody; clone B20-4.1.1 of mouse VEGF antibody
For more references about anti-mouse VEGF antibody (Clone: B20-4.1.1.1), please contact our scientific support team with message@sydlabs.com.